Bluebird bio — Investor Presentation (January 2016)
47 slides from Bluebird bio's investor presentation, Jan 11, 2016
Slide 1: Transforming the Lives of Patients with Severe Genetic and Rare Diseases
Transforming the Lives of Patients with Severe Genetic and Rare Diseases Making Hope a Reality Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue
Slide 3: bluebird bio: Why We Do What We Do
bluebird bio: Why We Do What We Do Our Vision – Make Hope a Reality Seeking to transform the lives of patients with severe genetic and rare diseases through the development of innovative gene therapy products. Ethan Cameron Aidan
Slide 4: Our Strategic Intent
Our Strategic Intent Severe Genetic Diseases Hematopoietic Stem Cells (HSCs) Immunotherapy T Cells Lentiviral Gene Delivery – Pure, Potent, Reproducible, Scalable Global Manufacturing Platform – Virus and Drug Product Genome Editing Platform – MegaTALs
Slide 5: 2015 Established Strong Fundamentals
2015 Established Strong Fundamentals Completed enrollment target of key CALD trial GREAT MOMENTUM HEADING INTO 2016 Treated first ever SCD patient with gene therapy Defined an accelerated U.S. and EU b-thalassemia regulatory path Closed several enabling oncology deals and filed IND Further built tea
Slide 6: 2016 Priorities
2016 Priorities β-THALASSEMIA HGB-204 & 205 β0/β0 Plan SICKLE CELL DISEASE HGB-205 HGB-206 CALD Starbeam Study Allo Transplant Study MULTIPLE MYELOMA CRB-401 Next-Generation PIPELINE Platform Improvements Innovative Science Launch Prep Development Strategy Regulatory Strategy Development Strategy Ne
Slide 7: Ecosystem Explosion
Ecosystem Explosion Competition Great For All (Especially Patients) Gene Therapy (20+) CAR/TCR/T Cell (25+) Gene Editing (8+) Mustang Therapeutics CARsgen
Slide 8: Gene Therapy Platform Capabilities Drive Pipeline
Gene Therapy Platform Capabilities Drive Pipeline
Slide 9: bluebird Lentiviral Stem Cell Platform
bluebird Lentiviral Stem Cell Platform Central nervous system (adrenoleukodystrophy) Blood disorders (thalassemia, sickle cell disease) Cancers Macrophage Erythrocyte T cell Granulocyte B cell Platelets Mature blood cells Progenitors Stem cells Hematopoietic Stem Cells Marrow Disease areas
Slide 10: How Our Gene Therapy Approach Works
How Our Gene Therapy Approach Works 1 2 3 4 Produce Viral Particle With Therapeutic Payload Isolate Target Cells From Patient Transduce Target Cells ex vivo Test & Re-infuse Gene Modified Cells Targeted Cells Gene Modified Cells Viral Particle
Slide 11: bluebird Pipeline Overview
bluebird Pipeline Overview Product Candidates Program Area Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Rare Hemoglobinopathies aes Wore barat BCMA covsre Five Prime Target Worldwide HPVAIBES TCR ste Parma Viromed Target EE other Programs Worewise LentiGlobin? Research Early Pipeline
Slide 12: Clinical Programs
Clinical Programs
Slide 13: β-thalassemia Major: Disease Overview
CURRENT TREATMENTS β-thalassemia Major: Disease Overview DISEASE EPIDEMIOLOGY Monogenic, severe anemia Loss of or reduced β-globin production Poor quality of life and shortened lifespan Frequent/chronic transfusions lead to iron overload & organ failure Ongoing iron chelation, frequently suboptimal
Slide 14: LentiGlobin: Innovative Vector Design
LentiGlobin: Innovative Vector Design Philippe Leboulch IN-VIVO BIOMARKER ANTI-SICKLING PROPERTIES polymerization destabilization V F L T bs bs V F L Q bs b-87
Slide 15: β-thalassemia Ongoing Clinical Trials
β-thalassemia Ongoing Clinical Trials Basis to Seek Conditional Approval in EU Phase 1/2, multi-center, global study N=18 subjects (up to 3 adolescents added) Centralized transduction for drug product manufacturing Positive data presented at ASH 2014 and 2015 (HGB-204) Phase 1/2, single-center study
Slide 16: Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion
Drug Product VCN and VCN in Peripheral Blood Leukocytes After Infusion Data presented at ASH 2015; as of October 28, 2015. DP VCN for all treated subjects. PBL VCN given for subjects with ≥2 months follow-up DP β0/β0 Non-β0/β0 1.8 1.6 1.4 1.2 1.0 0.8 0.6 0.4 0.2 0.0 5 4 3 2 0 3 6 9 12 15 18 21 1102
Slide 17: Updated Data Show High Levels of HbAT87Q Production After Infusion
Updated Data Continue to Show High Levels of HbAT87Q Production After Infusion Data presented at ASH 2015; as of October 28, 2015. Only includes subjects with ≥3 months of follow-up Median HbAT87Q g/dL 3.8 5.4 6.7 4.4 N=9 N=13 N=11 N=5 6.1 N=4 7.8 N=3 β0/β0 Non-β0/β0 1102 1103 1104 1106 1107 1108 11
Slide 18: Rapid and Sustained Transfusion Independence in non-β0/β0 Genotypes
Days Transfusion-Free Months Transfusion-Free* *Data presented at ASH 2015; as of October 28, 2015 for patients in HGB-204 and November 10, 2015 for patients in HGB-205 Subjects with non-β0/β0 genotypes stop transfusions shortly after DP infusion with RBC independence extending up to 23.4 months Pat
Slide 19: Reduction in Transfusions in Subjects with β0/β0 Genotype
Updated Data Show 33% to 100% Reduction in Transfusions in Subjects with β0/β0 Genotype Data presented at ASH 2015; as of October 28, 2015. Subjects with ≥6 m follow-up, shown to latest 3m interval, as of data cut-off. Subjects 1113 & 1115 had <6m follow-up. 52% 47% 33% 100% 1103 1106 1107 1110 Volu
Slide 20: Hemoglobin Levels by Genotype in Northstar Study
Hemoglobin Levels by Genotype in Northstar Study 9 g/dL Median Hemoglobin Concentrations at 6 Months HbF HbE/HbA (endogenous) HbAT87Q HbA2 HbA (transfused) Other Genotype n=5 β0/β0 Genotype n=4 4.9g/dL 5.0g/dL Difference in transfusion independence between genotypes explained by endogenous non-HbAT8
Slide 21: Evolving Clinical and Regulatory Plans
Pursue CONDITIONAL APPROVAL on the basis of data from ongoing Northstar (HGB-204) & HGB-205 studies as part of the Adaptive Licensing pilot Pursue ACCELERATED APPROVAL on the basis of data from planned pivotal HGB-207 & HGB-208 studies EU U.S. Initial U.S. regulatory strategy will focus on non-β0/β0
Slide 22: Sickle Cell Disease (SCD): Disease Overview
CURRENT TREATMENTS Sickle Cell Disease (SCD): Disease Overview DISEASE EPIDEMIOLOGY Monogenic, severe anemia Polymerization of β-globin chains deforms/sickles red blood cells Poor quality of life Pain crises, stroke, splenomegaly Shortened lifespan Non curative treatments U.S./EU prevalence ~150K U.
Slide 23: Why LentiGlobin May Treat Sickle Cell Disease
Why LentiGlobin May Treat Sickle Cell Disease These data argue that as little as 3g/dL (~30%) of therapeutic globin and gene marking as low as 20% could potentially achieve a disease-modifying effect LentiGlobin incorporates anti-sickling amino acid found in fetal hemoglobin Patients with SCD and he
Slide 24: HGB-206: Ongoing Trial in Severe Sickle Cell Disease
Open label, multi-center, U.S. based study Increased enrollment target from 8 subjects to 20 subjects to provide additional data and flexibility for regulatory strategy As of November 17, 2015, 11 subjects enrolled; bone marrow harvest completed for four subjects and in progress for five subjects Pr
Slide 25: HbAT87Q Production and Globin Change after Infusion
HbAT87Q Production and Globin Change after Infusion 1301 1303 1204 10 0 10 0 15 0 Months post drug product infusion Hb g/dL 1 2 3 6 9 12 10.9 12.0 10.6 11.4 11.7 9.1 8.5 7.6 5.5 10 8.6 7.8 9.2 8.5 HbAT87Q HbF HbA2 HbS HbA (transfused) 1.0 0.3 8.6 49% Anti-sickling Hemoglobin 16% Anti-sickling Hemogl
Slide 26: Cerebral Adrenoleukodystrophy (CALD): Disease Overview
CURRENT TREATMENTS Cerebral Adrenoleukodystrophy (CALD): Disease Overview DISEASE EPIDEMIOLOGY Ultra-orphan, X-linked, monogenic, neurological disorder Mutated gene results in toxic buildup of very long chain fatty acids Leads to cerebral inflammation & demyelination Untreated cerebral ALD leads to
Slide 27: Starbeam Study for Cerebral ALD: Interim Clinical Data Expected in 2016
Starbeam Study for Cerebral Adenoleukodystrophy: Interim Clinical Data Expected in 2016 12 months 18 months 24 months Natural Course of Disease Open label, single arm, multi-center, global study (n=18) Abstract Submitted for April 2016 AAN Meeting
Slide 28: Research Platform
Research Platform
Slide 29: Research Platform and Strategy
Research Platform and Strategy mRNA SynBio Lentivirus T Cell HSC Platform T Cell Platform Future Pipeline MegaTALs Strengthening existing platforms HSC Ex Vivo Powerful research platform with multiple tools and technologies to: Enhance the therapeutic potential of current clinical programs Apply com
Slide 30: Hypothesis: Improving VCN in the LentiGlobin Drug Product
Hypothesis: Improving VCN in the LentiGlobin Drug Product Should Increase T87Q Levels and Further Improve Clinical Benefit
Slide 31: Identifying Compounds that Improve Transduction
Improving VCN in the LentiGlobin Drug Product Identifying Compounds that Improve Transduction Goal: Increased VCN via increased transduction efficiency (% HSCs transduced)
Slide 32: Selected Compounds from Screening Results
Improving VCN in the Drug Product Selected Compounds from Screening Results Experiment performed with pre-characterized “hard to transduce” donor HSCs Similar fold improvement in VCN obtained across a wide range of donors, lentiviral vectors and LVV lots Process is well tolerated Standard Conditions
Slide 33: Markedly Increased % Corrected HSCs
Improving VCN in the LentiGlobin Drug Product Markedly Increased % Corrected HSCs % Transduced Cells Standard Conditions Single-cell PCR assay demonstrates marked increase in transduction efficiency Up to ~90% of the cells transduced using most optimized conditions *preliminary research findings
Slide 34: bluebird Gene Editing Approach
bluebird Gene Editing Approach MegaTAL Technology Expertise in homing endonucleases (HE) and MegaTALs Robust nuclease discovery platform, proprietary database, broad IP Multiple advantages of HE and MegaTALs Naturally occurring proteins Highly specific and efficient Compact size Broad range of thera
Slide 35: MegaTAL Enabled Targeted Gene Addition
Demonstrates power of megaTAL and AAV platforms – supports NextGen HSC and Cancer Immunotherapy Programs MegaTAL Enabled Targeted Gene Addition Precision Offers Promise of Enhanced Efficacy and Safety
Slide 36: Immuno-Oncology
Immuno-Oncology
Slide 37: Differentiated Oncology Approach
Deliver differentiated, best-in-class, genetically modified cellular products to patients suffering from cancer. Differentiated Oncology Approach BCMA (Partnered with Celgene) HPV (Partnered with Kite) Five Prime Target Viromed Target LVV Technology Manufacturing Advances (Pl3K) LVV Technology Manuf
Slide 38: BCMA: A Promising Target in Multiple Myeloma
B cell maturation antigen (BCMA) is a member of the TNF receptor superfamily. BCMA binds B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA is expressed by plasma cells and some mature B cells. Mice deficient in BCMA are healthy and have normal numbers of B cells, but
Slide 39: bb2121 Vector Design
bb2121 Vector Design SP Anti-BCMA scFv CD3z 41BB MND CD8 bb2121 CAR Expression Control CAR Anti-BCMA CAR Anti-BCMA CAR Expression Anti-BCMA CAR – bb2121
Slide 40: Single Treatment with bb2121 CAR T Cells Clears Animals of MM
Tumor treatment Bortezomib A Single Treatment with bb2121 CAR T Cells Clears Animals of MM and Results in 100% Survival Survival
Slide 41: An Efficient CAR T Drug Product Manufacturing Process
(Day 3-10) Expansion (Day 10) Harvest/Cryopreservation (Day -1) Leukapheresis Gene modified T cells infused back to patient (Day 0) PBMC Isolation, Culture Initiation/Activation (Day 1) Transduction with LVV Gene modified T cells Step 1 Step 2 Step 3 Step 4 Treatment An Efficient CAR T Drug Product
Slide 42: Promising Clinical Proof-of-Concept for bb2121 in NCI Study
Promising Clinical Proof-of-Concept for bb2121 in NCI Anti-BCMA Latebreaker NCI-sponsored Phase 1 first-in-human study of anti-BCMA CAR T therapy in heavily pre-treated patients with multiple myeloma Presenter and PI Jim Kochenderfer will serve as a PI for bluebird Phase 1 study of bb2121 bb2121 on
Slide 43: CRB-401 (Refractory Multiple Myeloma)
U.S.-based, 6-10 clinical sites – including NCI N = 40 patients, standard 3+3 Design based on CAR+ T cells doses Primary endpoint = Determine the maximally tolerated dose and recommended phase 2 dose (RP2D) Subjects must have received 3 prior regimens including a proteasome inhibitor (bortezomib, ca
Slide 44: Deepening Pipeline
Deepening Pipeline Product Candidates ProgranAren Preclinical Phase 1/2 Phase 2/3 Rights/Partner CNS Diseases Lent” won Rare Hemoglobinopathies Beta-thalassemia Major’ Worldwide Severe Sickle Cell Disease Worldwide Oncology bb2121 BCMA Celgene Next Gen BCMA Celgene Five Prime Target Worldwide HPV-16
Slide 45: bluebird bio 2020: The Gene Therapy Products Company
2010 - 2014 bluebird bio 2020: The Gene Therapy Products Company 2015 - 2020 Early POC Clinical Data Infrastructure & Capabilities Core Program Clinical Data Broad Gene Therapy Infrastructure Translational Development Manufacturing Clinical Regulatory Tech & Global Collaborations and New Products Gl
Slide 46: Anticipated Significant 2016 Milestones
Anticipated Significant 2016 Milestones FIRST HALF 2016 SECOND HALF 2016 LentiGlobin Thal and SCD Data Update at ASH Initiate CRB-401 Study of bb2121 (Q1) CCALD Data Update at AAN (April) Initiate HGB-207 Study of LentiGlobin Cash Runway Through 2018
Slide 47: Transforming the Lives of Patients with Severe Genetic and Rare Diseases
Transforming the Lives of Patients with Severe Genetic and Rare Diseases Making Hope a Reality